ArticleCase reports in cardiology2026
Guidewire Ablation via Coronary Venous System for Frequent VPBs: A Case Report.
Article in Case reports in cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guidewire Ablation via Coronary Venous System for Frequent VPBs: A Case Report.Case reports in cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventricular arrhythmias originating from the left ventricular summit (LVS) are challenging to treat with conventional catheter ablation due to the region's complex anatomy, proximity to coronary arteries, and epicardial fat coverage. Percutaneous guidewire ablation via the coronary venous system (CVS) provides a minimally invasive therapeutic option for refractory arrhythmias in this area. Case Presentation: Herein, we present the case of a 60-year-old Asian female patient who had a 1-year history of palpitations and was diagnosed with symptomatic, frequent ventricular premature beats (VPBs). The patient exhibited an inadequate response to metoprolol and amiodarone as pharmacological therapy and conventional ablation approaches. Following guidewire ablation via the CVS, the VPBs were eliminated entirely, her palpitations fully resolved, and no procedure-related complications, such as coronary artery injury or thrombosis, were observed. During follow-up, there was no recurrence of VPBs, and left ventricular function remained normal. Conclusion: By employing precise mapping, individualized parameter settings, and strict safety monitoring, percutaneous guidewire ablation via the CVS can effectively treat drug-refractory VPBs originating from the LVS. Importantly, this approach could serve as a complementary option when traditional ablation methods are unsuccessful, offering a feasible therapeutic strategy for complex ventricular arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.